U.S. Markets close in 2 hrs 35 mins
  • S&P 500

    4,176.54
    +8.95 (+0.21%)
     
  • Dow 30

    34,370.17
    +139.83 (+0.41%)
     
  • Nasdaq

    13,551.03
    -31.40 (-0.23%)
     
  • Russell 2000

    2,223.06
    -18.30 (-0.82%)
     
  • Crude Oil

    65.05
    -0.58 (-0.88%)
     
  • Gold

    1,814.70
    +30.40 (+1.70%)
     
  • Silver

    27.51
    +0.99 (+3.73%)
     
  • EUR/USD

    1.2054
    +0.0045 (+0.3737%)
     
  • 10-Yr Bond

    1.5680
    -0.0160 (-1.01%)
     
  • Vix

    19.14
    -0.01 (-0.05%)
     
  • GBP/USD

    1.3887
    -0.0020 (-0.1472%)
     
  • USD/JPY

    109.1010
    -0.0880 (-0.0806%)
     
  • BTC-USD

    56,957.74
    -663.88 (-1.15%)
     
  • CMC Crypto 200

    1,485.57
    +14.15 (+0.96%)
     
  • FTSE 100

    7,076.17
    +36.87 (+0.52%)
     
  • Nikkei 225

    29,331.37
    +518.74 (+1.80%)
     

The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations

Shanthi Rexaline
·2 min read

Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts and pre-announcements in light of the COVID-19 impact.

The stock that made headlines during the week was Amarin Corporation plc (NASDAQ: AMRN), which slumped on an adverse court ruling.

The following are catalysts that could impact biotech stocks in the unfolding week.

The focus is likely to stay on pre-clinical and clinical updates from companies developing therapies and/or vaccines for SARS-CoV-2. More companies are expected to update investors with preliminary first-quarter results that factor in the COVID-19 impact.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

Conferences

  • Goldman Sachs Cell Therapy Day: April 6

  • 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 7 in Boston, Massachusetts

  • Canaccord Genuity Horizons in Oncology Virtual Event: April 8 in Boston 

  • 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 9 in San Francisco, California

Clinical Readouts

Menlo Therapeutics Inc (NASDAQ: MNLO): top-line data from two ongoing serlopitant Phase 3 studies in pruritus associated with prurigo nodularis (late March/early April)

Oragenics Inc (NYSE: OGEN): Results from the Phase 2 study of AG013 in oral mucositis (early 2020)

Earnings

  • AngioDynamics, Inc. (NASDAQ: ANGO) (Tuesday after the close)

  • PAVmed Inc (NASDAQ: PAVM) (Thursday after the close)

IPOs

Keros Therapeutics, which develops therapies for hematological and neuromuscular disorders, plans to offer 5 million shares in an IPO priced between $14 and $16. The company has applied to list its shares on the Nasdaq under the ticker symbol "KROS."

IPO Quiet Period Expiry

Imara Inc (NASDAQ: IMRA)

Related Links:

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

10 Biotech Winners And Losers In Q1

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.